The Japan Society of Obstetrics and Gynecology collects and analyzes annual data on gynecologic cancers from member institutions. We present the Patient Annual Report for 2014 and the Treatment Annual Report for 2009. Data on 7436 patients with cervical cancer, 9673 with endometrial cancer, 5924 with ovarian cancer, and 1909 with ovarian borderline tumor for whom treatment was initiated in 2014 were summarized in the Patient Annual Report. Stage I accounted for 55.6%, stage II for 22.9%, stage III for 10.2%, and stage IV for 11.2% of all patients with cervical cancer. Stage I accounted for 72.3%, stage II for 6.0%, stage III for 14.1%, and stage IV for 7.7% of all patients with endometrial cancer. Stage I accounted for 43.3%, stage II for 9.1%, stage III for 27.6%, and stage IV for 7.2% of all patients with ovarian cancer. Data on the prognosis of 4126 patients with cervical cancer, 4613 with endometrial cancer, and 3205 with ovarian cancer for whom treatment was initiated in 2009 were analyzed in the Treatment Annual Report. Survival was analyzed by using the Kaplan-Meier method, the logrank test and the Wilcoxon test. The 5-year overall survival rates for patients with cervical cancer were 92.4% for stage I, 76.7% for stage II, 54.3% for stage III, and 25.2% for stage IV. The equivalent rates for patients with endometrial cancer were 94.6%, 89.4%, 78.3%, and 25.0%, respectively; and those for patients with ovarian cancer (surface epithelial-stromal tumors) were 90.5%, 78.8%, 46.0%, and 25.1%, respectively.
Introduction
The Japan Society of Obstetrics and Gynecology (JSOG) collects annual data on the clinicopathologic factors and prognoses of gynecologic cancers from member institutions every year and analyzes this information to investigate the trends in gynecologic cancers in Japan. We report some of the results of the Patient Annual Report for 2014 and the Treatment Annual Report for 2009.
The data presented in this paper are quoted and modified for English presentation from previous reports written in Japanese.
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Patients and Methods
For patients whose treatment was initiated in 2014, data were collected, retrospectively analyzed, and summarized in the Patient Annual Report for 2014. For patients whose treatment was initiated in 2009, data on prognosis were collected, analyzed, and summarized in the Treatment Annual Report for 2009, assuming a 5-year follow-up period was necessary.
The present study was conducted with the approval of the ethics committee of JSOG.
Patient Annual Report for 2014
The subjects included 13 757 patients with cervical intraepithelial neoplasia 3 (CIN3), 7436 with stage I-IV cervical cancer, 664 with atypical endometrial hyperplasia, 9673 with stage I-IV endometrial cancer, 5924 with ovarian cancer, and 1909 with borderline ovarian tumor. These patients were histopathologically diagnosed in each of the 411 member institutions of JSOG and were administered treatment between January and December 2014. The clinical stages of cervical cancer and surgical stages of endometrial cancer were based on the FIGO 2008 staging system. The surgical stages for ovarian cancer, including borderline ovarian tumor, were based on the FIGO 1988 staging system. Data on age, clinical stage, histologic type, and treatment were collected for patients with cervical cancer; data on age, surgical stage, histologic type, and treatment were collected for patients with endometrial cancer; and data on age, surgical stage, histologic type, and treatment were collected for patients with ovarian cancer and borderline ovarian tumor. Patient information was anonymized in a linkable fashion and registered from each institution onto the website of JSOG.
Statistical analyses were performed at the Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan.
Treatment Annual Report for 2009
In all, 286 institutions provided data on the 3-year and 5-year prognoses of patients registered in any of the member institutions of JSOG between January and December 2009 and those reported in the Patient Annual Report for 
Statistical analysis
The overall survival rates were analyzed by the KaplanMeier method and statistical significance was determined using the log-rank test and Wilcoxon test.
Results
Patient Annual Report for 2014
Cervical cancer Age distribution (Fig. 1) . Patients aged 30-39, 40-49, 50-59, and 60-69 years accounted for 18.7%, 24.7%, 17.8%, and 18.1% of all registered cervical cancer patients, respectively. These findings demonstrated that the disease predominantly affected women in their 40s and 30s and that older patients tended to be in the more advanced stages than younger patients. (Fig. 2) The other rare histologic types encountered are shown in Table 1 .
Stages
Treatment (Fig. 3) . Of the cervical cancer patients, 35.1% underwent surgery alone, 21.4% received chemotherapy in addition to radiotherapy, 14.5% received chemotherapy in addition to surgery, 12.0% received radiotherapy alone, and 8.7% received radiotherapy and Histologic types (Table 2) . Endometrioid adenocarcinoma was the most common histologic type of endometrial cancer, accounting for 81.6% of all tumors. Other histologic types included serous adenocarcinoma (5.5%), clear cell adenocarcinoma (2.2%), and mixed carcinoma (2.3%). Carcinosarcoma was observed in 4.9% of endometrial cancer patients.
Treatment (Fig. 6 ). Of the endometrial cancer patients, 57.3% underwent surgery alone, 36.9% received chemotherapy and other therapies, such as hormone therapy after surgery, and 1.5% received radiotherapy after surgery. Of the remaining patients, 2.5% received chemotherapy alone or with hormone therapy, and 1.3% received radiotherapy alone or with chemotherapy and hormonal therapy.
Ovarian cancer (all histologic types) Age distribution (Fig. 7) . Patients aged 60-69, 50-59, and 40-49 years accounted for 27.2%, 26.2%, and 20.4%, respectively, of all ovarian cancer patients; this indicated that the disease predominantly affected women in their 50s and 60s.
Surgical stages (Fig. 8) Histologic types (Table 3) . Surface epithelial-stromal tumors accounted for 95.4%, serous adenocarcinoma for 35.7%, clear cell adenocarcinoma for 24.8%, endometrioid adenocarcinoma for 17.5%, and mucinous adenocarcinoma for 9.6% of all ovarian cancer tumors. Sex cord-stromal and germ cell tumors were observed in 0.3% and 3.0% of ovarian cancer patients, respectively. Treatment (Fig. 9 ). Of the ovarian cancer patients, 78.2% received chemotherapy after surgery, 19.4% underwent surgery alone, and 1.2% received chemotherapy.
Borderline ovarian tumor Surgical stages (Fig. 8) Histologic types (Table 4) . Mucinous tumors accounted for 58.0%, serous tumors for 20.0%, endometrioid tumors for 2.7%, and mixed tumors for 2.7% of all borderline ovarian tumors. In addition, granulosa cell tumors accounted for 8.2% and immature teratomas (G1, G2) for 3.5% of borderline ovarian tumors.
Treatment (Fig. 10) . Of the borderline ovarian tumor patients, 94.4% underwent surgery alone and 5.2% received chemotherapy after surgery.
Treatment Annual Report for 2009
Cervical cancer Overall survival by clinical stage (Fig. 11) . The overall survival (OS) rates for cervical cancer by clinical stage are shown in Figure 11 . OS by histologic type (Fig. 12) . The OS rates for cervical cancer by histologic type are shown in Figure 12 . The 5-year OS rates were 80.1%, 74.7%, 76.7%, and 57.5% in patients with squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and other cancers, respectively. Patients with squamous cell carcinoma had a significantly better survival compared to those with adenocarcinoma (P = 0.0002), adenosquamous cell carcinoma (P<0.0001), and other cancers (P<0.0001).
Patients with adenosquamous cell carcinoma had a significantly better prognosis compared with those with other cancers (P<0.0001). Patients with adenocarcinoma had no significantly different survival compared with those with adenosquamous cell carcinoma (P = 0.2353) and other cancers (P = 0.8336).
Endometrial cancer OS by surgical stage of endometrial cancer (Fig. 13) . The OS rates for endometrial cancer by surgical stage are shown in Figure 13 . OS by histologic type of endometrial cancer (Fig. 14) . The 5-year OS rates for endometrial cancer were 95.4%, 88.7%, 73.6%, 53.9%, 79.3%, and 55.2% for patients with G1, G2, G3 endometrioid adenocarcinoma, serous adenocarcinoma, clear cell adenocarcinoma, and carcinosarcoma, respectively. Patients with G1 endometrioid adenocarcinoma had a significantly better prognosis compared with those with G2 and G3 endometrioid adenocarcinoma, serous adenocarcinoma, clear cell adenocarcinoma, and carcinosarcoma (P<0.0001). Patients with G2 endometrioid adenocarcinoma had a significantly better prognosis compared with those with G3 endometrioid adenocarcinoma (P<0.0001), serous adenocarcinoma (P<0.0001), clear cell adenocarcinoma (P = 0.0003), and carcinosarcoma (P<0.0001). Patients with G3 endometrioid adenocarcinoma had a Ovarian cancer (surface epithelial-stromal tumors) OS by surgical stage of ovarian cancer (Fig. 15) . The OS rates for ovarian cancer by surgical stage are shown in Figure 15 . OS by histologic type of ovarian cancer (Fig. 16) The OS rates for ovarian cancer by histologic type are shown in Figure 16 . Patients with serous adenocarcinoma had a significantly poorer prognosis compared with those with mucinous adenocarcinoma (P<0.0001), endometrioid adenocarcinoma (P<0.0001), and clear cell adenocarcinoma (P<0.0001). Patients with endometrioid adenocarcinoma had a most favorable prognosis and had significantly better survival compared with those with mucinous adenocarcinoma (P = 0.0165). 
Discussion
In this analysis, the number of patients with gynecologic cancer, especially endometrial cancer, had increased from the analysis of 2013 despite the decrease of the number of member institutions in JSOG (423 institutions in 2013 to 411 institutions in 2014). This increase seemed to be influenced by the increase in the incidence of endometrial cancer, cervical cancer, and ovarian cancer in Japan.
Since the Patient Annual Report in 2012, the FIGO 2008 staging classification has been adopted for the statistical analysis of cervical and endometrial cancers, whilst the FIGO 1988 staging classification was still adopted for the statistical analysis of ovarian cancer in the present report. FIGO 2014 staging classification of ovarian cancer was adopted by JSOG in April 2014 and was announced to the members of JSOG in November 2014. Registration of patient with ovarian cancer using the FIGO 2014 staging classification started in 2015. Carcinoma in situ, which was previously defined as stage 0 cervical cancer, was excluded from FIGO staging. In the Patient Annual Report, carcinoma in situ was included with severe dysplasia as CIN3. Atypical endometrial hyperplasia, which was previously defined as stage 0 endometrial cancer, was also excluded from FIGO staging, but the number of patients with atypical endometrial hyperplasia was reported in the present Annual Report. There were no significant differences from 2013 data in the distribution of patients by the stages and histologic types of cervical cancer, endometrial cancer, ovarian cancer, and borderline ovarian tumors. For the Treatment Annual Reports for 2009, the FIGO 1988 staging classification was adopted for this statistical analysis of cervical, endometrial, and ovarian cancers. Prognosis was analyzed by the Kaplan-Meier method. As in the previous report, [3] [4] [5] [6] information from institutions where prognoses were untraceable for ≥20% of patients was excluded from the analysis in the present study. Consequently, among patients with a known prognosis, 69.8% of cervical cancer, 75.6% of endometrial cancer, and 79.7% of ovarian cancer patients were included in the analysis of prognosis. Data management was re-evaluated and improved by the committee and queries of the data were programmed to secure the quality of data. Queries were sent to the member institutions to receive adequate responses.
We thus presented the Patient Annual Report for 2014 and the Treatment Annual Report for 2009 on gynecologic tumors (cervical, endometrial, and ovarian cancers and borderline ovarian tumor) in Japan. We hope the information will contribute to the future analyses of these gynecologic cancers. 
